A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
Clinical trial NCT06930573 · RECRUITING
Trial details
- NCT number
- NCT06930573
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Status
- RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-04
- Primary completion
- 2026-05-24
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.